Roche pens backloaded $2B deal with Atavistik to discover allosteric CVRM drugs
Fuente:
FierceBiotech
Roche has penned a backloaded $2 billion deal with hematology biotech Atavistik Bio to develop allosteric small molecules for cardiometabolic diseases.